BOLD
$1.19+0.04 (+3.48%)
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA).
Recent News
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know
Boundless Bio, Inc. (BOLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).